Le Conseil d’examen du prix des médicaments brevetés (CEPMB) published today, within the framework of the research initiative du Système national d’information sur l’utilisation des médicaments prescrits (SNIUMP), the report Pénuries de médicaments au Canada et leurs répercussions sur les régimes publics d’assurance-medicaments, from 2017-2018 to 2019-2020, which gives an overview of the repercussions of pénuries de médicaments au Canada, in mettant l’accent sur les effets sur les régimes publics d “assurance-médicaments du Canada et their beneficiaries.
OTTAWA, ON, Sept. 21 2022 /CNW/ – What report is le premier à avoir recours au website sur les pénuries de médicaments au Canada to give an aperçu de la question des pénuries de médicaments au Canada. The report will consider reports of drug shortages provided from April 1, 2017 to March 31, 2020. The study period, which preceded the COVID-19 pandemic, provides future research with a benchmark for assessing the pandemic’s repercussions on the ‘approvisione en mediciones’.
According to the report, shortages were reported for 29% of drugs sold in Canada in 2019-2020. However, 91% of drug reports on drugs were not patented by multiple ancillary sources, it was possible to substitute a product of another manufacturer. Therefore, only a small number of shortages was associated with a strong base of names of beneficiaries of the public drug insurance schemes present des demandes de remboursement. These findings provided in an important context, but are not visible to minimize the adverse effects that certain diseases can have on individual patients and on the health system, especially when it is not possible to replace other targeted medical products. par les pénuries or lorsque la forme posologique or drug concentration are not interchangeable.
Made in brief
• Between April 1, 2017 and March 31, 2020, a total of 8,558 shortage reports were submitted by Canadian manufacturers, for an average of 238 new reports per month.
• In 2019-2020, shortages were reported for 29% of drugs sold in Canada. The generic drugs and the drugs whose cost of treatment was weak (less than $10,000/year) showed high shortage rates. No link has been established between le prix relatif des médicaments à l’échelle internationale et les taux de pénurie au Canada.
• The great majority (91 %) of shortage reports concern non-patented medications from multiple sources, to which it was possible in most cases to substitute the same pharmaceutical ingredients from another manufacturer. Les médicaments brevetés et les médicaments non brevetés de unique source représentaient 7 % et 2 % des médicaments for which a shortage has been signaled, respectively.
• Plus de la moitie (55 %) des pénuries de médicaments signalées are absorbed in les three mois after their appearance. Around les trois quarts des pénuries (74 %) were indicated as “solutions” within six months of their occurrence. Les pénuries de médicaments brevetés et de médicaments non brevetés de unique source are solved more quickly because those of medicines are not brevetés from multiple sources.
• La plupart des pénuries ne perturbent pas équipementaire les tendances relative aux éspénieres pour les régimes publics.
Publication Index Santé : 2022-09-22 – Number of visits since publication date : 8
In pounds on Index Santé: